<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20031101//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3206007</article-id><article-id pub-id-type="pmid">22069505</article-id><article-id pub-id-type="publisher-id">PNTD-D-11-00600</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0001375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Macromolecular Structure Analysis</subject><subj-group><subject>Protein Structure</subject></subj-group></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Immunity to Infections</subject></subj-group></subj-group><subj-group><subject>Immunoglobulins</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Parasitology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Cardiovascular</subject><subj-group><subject>Cardiomyopathies</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Crystal Structure of the Complex mAb 17.2 and the C-Terminal Region of Trypanosoma cruzi P2β Protein: Implications in Cross-Reactivity </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Crystal Structure of the mAb 17.2-R13 Complex</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pizarro</surname><given-names>Juan Carlos</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="fn1">
<sup>¤</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Boulot</surname><given-names>Ginette</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bentley</surname><given-names>Graham A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gómez</surname><given-names>Karina A.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hoebeke</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hontebeyrie</surname><given-names>Mireille</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Levin</surname><given-names>Mariano J.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Smulski</surname><given-names>Cristian R.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Unité d'Immunologie Structurale, Institut Pasteur, Paris, France</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Centre National de la Recherche Scientifique, Unité de Recherche Associée 2185, Paris, France</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Laboratorio de Biología Molecular de la Enfermedad de Chagas, INGEBI-CONICET, Buenos Aires, Argentina</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>UPR9021 du CNRS, Strasbourg, France</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Institut Pasteur, Paris, France</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Santiago</surname><given-names>Helton da Costa</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">National Institutes of Health, United States of America</aff><author-notes><corresp id="cor1">* E-mail: <email>c.smulski@unistra.fr</email></corresp><fn id="fn1" fn-type="current-aff"><p><text><SENT sid="1" pm="."><plain>¤: Current address: Structural Genomic Consortium (SGC), University of Toronto, Toronto, Canada </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: GAB MJL MH CRS. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: JCP GB GAB KAG MH CRS. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: JCP GAB KAG JH CRS. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: KAG MJL MH GAB CRS. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: JCP GAB MH CRS. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><month>11</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>1</day><month>11</month><year>2011</year></pub-date><volume>5</volume><issue>11</issue><elocation-id>e1375</elocation-id><history><date date-type="received"><day>18</day><month>6</month><year>2011</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2011</year></date></history><permissions><copyright-statement>Pizarro et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>Patients with Chronic Chagas' Heart Disease possess high levels of antibodies against the carboxyl-terminal end of the ribosomal P2ß protein of Trypanosoma cruzi (TcP2ß). </plain></SENT>
<SENT sid="8" pm="."><plain>These antibodies, as well as the murine monoclonal antibody (mAb) 17.2, recognize the last 13 amino acids of TcP2ß (called the R13 epitope: EEEDDDMGFGLFD) and are able to cross-react with, and stimulate, the ß1 adrenergic receptor (ß1-AR). </plain></SENT>
<SENT sid="9" pm="."><plain>Indeed, the mAb 17.2 was able to specifically detect human β1-AR, stably transfected into HEK cells, by flow cytometry and to induce repolarisation abnormalities and first degree atrioventricular conduction block after passive transfer to naïve mice. </plain></SENT>
<SENT sid="10" pm="."><plain>To study the structural basis of this cross-reactivity, we determined the crystal structure of the Fab region of the mAb 17.2 alone at 2.31 Å resolution and in complex with the R13 peptide at 1.89 Å resolution. </plain></SENT>
<SENT sid="11" pm="."><plain>We identified as key contact residues on R13 peptide Glu3, Asp6 and Phe9 as was previously shown by alanine scanning. </plain></SENT>
<SENT sid="12" pm="."><plain>Additionally, we generated a model of human β1-AR to elucidate the interaction with anti-R13 antibodies. </plain></SENT>
<SENT sid="13" pm="."><plain>These data provide an understanding of the molecular basis of cross-reactive antibodies induced by chronic infection with Trypanosoma cruzi. </plain></SENT>
</text></SecTag></p></abstract><abstract abstract-type="summary"><title><text><SENT sid="14" pm="."><plain>Author Summary </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15" pm="."><plain>Trypanosoma cruzi is a protozoan parasite responsible for Chagas disease. </plain></SENT>
<SENT sid="16" pm="."><plain>Chronic Chagas' heart disease (cChHD) is not only the most frequent and severe consequence of the chronic infection by T. cruzi, but is also the main cause of cardiomyopathy in South and Central America. </plain></SENT>
<SENT sid="17" pm="."><plain>Patients with cChHD possess high levels of antibodies against the carboxyl-terminal tail of the ribosomal P proteins of T. cruzi (called the R13 epitope). </plain></SENT>
<SENT sid="18" pm="."><plain>These antibodies, as well as the murine monoclonal antibody (mAb) 17.2, are able to cross-react with, and stimulate, the ß1 adrenergic receptor (ß1-AR). </plain></SENT>
<SENT sid="19" pm="."><plain>Indeed, the mAb 17.2 was able to specifically detect human β1-AR and induce some of the classical cardiac symptoms after passive transfer to mice. </plain></SENT>
<SENT sid="20" pm="."><plain>To study the structural basis of this cross-reactivity, we determined the crystal structure of the Fab region of the mAb 17.2 alone and in complex with R13. </plain></SENT>
<SENT sid="21" pm="."><plain>Additionally, we generated a model of human β1-AR to elucidate the interaction with anti-R13 antibodies in order to understand the molecular basis of cross-reactive antibodies induced by chronic infection with T. cruzi. </plain></SENT>
</text></SecTag></p></abstract><counts><page-count count="10"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="22" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="23" pm="."><plain>Trypanosoma cruzi, the etiological agent of Chagas' disease, affects approximately 10–12 million people from different endemic regions in Latin America [1], killing more than 15,000 each year [2], [3]. </plain></SENT>
<SENT sid="24" pm="."><plain>It is also carried by hundreds of thousands of people in Europe (especially Spain and Portugal), the United States, Canada, Japan and Australia, mostly by Latin American immigrants. </plain></SENT>
<SENT sid="25" pm="."><plain>Accordingly, infection control of blood banks has been recently implemented outside endemic regions [4]. </plain></SENT>
<SENT sid="26" pm="."><plain>Chagas' disease shows a variable clinical course, which ranges from an acute phase, with parasitemia and asymptomatic features, to serious chronic symptomatic stages characterized by low or no parasitemia, positive serology and involving clinical cardiac, gastrointestinal or neurological disorders [3], [5]. </plain></SENT>
<SENT sid="27" pm="."><plain>The cardiac form, referred as chronic Chagas' heart disease (cChHD), is not only the most frequent and severe consequence of the chronic infection by T. cruzi, but is also the main cause of cardiomyopathy in South and Central America [6]. </plain></SENT>
<SENT sid="28" pm="."><plain>Among other clinical features, cChHD is an arrhythmogenic cardiomyopathy with high prevalence of right bundle branch block, left anterior hemi block, sinus node dysfunction and complex supraventricular arrhythmias [7], [8]; mega disorders of colon or esophagus and neurological disorders are less frequent (around 5% of the infected people) [9], [10]. </plain></SENT>
<SENT sid="29" pm="."><plain>To date, the mechanisms of the pathophysiology of Chagas' disease are not completely understood and two main hypotheses have been proposed: the first is based on the essential role of the parasite in tissular damage while the second argues for an auto reactive process resulting from an impaired immune response associated with molecular mimicry [11], [12], [13]. </plain></SENT>
<SENT sid="30" pm="."><plain>Different experimental approaches have shown that both mechanisms may be involved in the chagasic pathology because of the persistence of the parasite in chronic phase [14] and of the presence of parasite antigens carrying epitopes common to host molecules [15]. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>In 1989, Levin et al. selected and cloned the first parasite molecule, called JL5, presenting a molecular mimicry of a human molecule, using serum from a chronically infected person with cChHD [16], [17]. </plain></SENT>
<SENT sid="32" pm="."><plain>The fine epitope recognized by patients with cChHD was located at the C-terminal end of the T. cruzi ribosomal P2β protein (TcP2β) and was named R13 (EEEDDDMGFGLFD) [15], [18], [19], [20]. </plain></SENT>
<SENT sid="33" pm="."><plain>This highly antigenic acidic epitope bears similarity to an acidic motif (AESDEA) on the second extracellular loop of cardiac β1-adrenergic receptor (β1-AR) [21], [22]. </plain></SENT>
<SENT sid="34" pm="."><plain>In addition, a significant correlation between the high level of anti-R13 antibodies (Abs) and ventricular arrhythmias was observed [23], consistent with the hypothesis that R13-specific anti-TcP2β Abs are able to cross-react with and stimulate the β1-AR [19], [20], [21], [22], [23], [24], [25]. </plain></SENT>
<SENT sid="35" pm="."><plain>Alanine-mutation scanning experiments on the R13 epitope using different immuno-purified anti-R13 Abs illustrated the complexity of the anti-R13 humoral response since each of the eight anti-R13 Ab preparations presented a unique epitope recognition pattern [23]. </plain></SENT>
<SENT sid="36" pm="."><plain>Despite this extreme heterogeneity, it was possible to determine a common reactivity profile where Glu3, and to a lesser extent, Asp6 and Phe9 were essential [23]. </plain></SENT>
<SENT sid="37" pm="."><plain>Indeed, the C-terminal end of the human ribosomal P proteins has one single amino acid change in the third residue (Glu3Ser), a change that diminished the affinity of mAb 17.2 for the corresponding mammalian peptide by about two orders of magnitude [22]. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>Mice immunized with different recombinant TcP2β proteins (GST or His fusion proteins) and different adjuvants (CFA or ALU) induced a diverse response along the protein sequence. </plain></SENT>
<SENT sid="39" pm="."><plain>Strikingly, Abs from infected animals recognized only the C-terminal region of the protein (R13 epitope). </plain></SENT>
<SENT sid="40" pm="."><plain>These different antiserum showed that only Abs specific for the C-terminus were able to increase the beating frequency of cardiomyocytes from neonatal rats in vitro by selective stimulation of the β1-AR [24]. </plain></SENT>
<SENT sid="41" pm="."><plain>These immunization data led to protocols for the production of a monoclonal antibody directed against the R13 epitope, the mAb 17.2. </plain></SENT>
<SENT sid="42" pm="."><plain>This mAb was demonstrated to i) recognize a linear epitope of the C-terminal end of TcP2β protein (R13), ii) react with peptides derived from the second extracellular loop of the human β1-AR, iii) induce a dose-dependent increase on the beating frequency of cardiomyocytes in culture that is abolished by bisoprolol, a specific β1-AR antagonist [22], and iv) provoke apoptosis in murine cardiac cell lines, HL-1 [26]. </plain></SENT>
</text></p><p><text><SENT sid="43" pm="."><plain>In the present work, we report the three-dimensional structure of the Fab fragment of mAb 17.2 determined by X-ray crystallography, alone and in complex with its cognate peptide epitope, providing a description of structural changes that occur upon binding the antigen. </plain></SENT>
<SENT sid="44" pm="."><plain>The mAb 17.2 was shown by flow cytometry to specifically detect HEK cells transfected with the human β1-AR. </plain></SENT>
<SENT sid="45" pm="."><plain>In addition, passive transfer to naïve mice induced some of the classical symptoms of the Chagasic cardiomyopathy, such as repolarisation abnormalities and first degree atrioventricular (AV) conduction block. </plain></SENT>
<SENT sid="46" pm="."><plain>Finally, we discuss the relationship between epitope mimicry and bystander activity of anti-R13 Abs on the β1-AR using our crystal structure of the Fab 17.2 in complex with a model of the human β1-AR constructed from the turkey β1-AR structure that was recently determined [27]. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s2"><title><text><SENT sid="47" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="48" pm="."><plain>1. </plain></SENT>
<SENT sid="49" pm="."><plain>Ethics statement </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>The research was conducted in accordance with the European Community guidelines for use of experimental animals. </plain></SENT>
<SENT sid="51" pm="."><plain>The IBMC animal house facilities are approved by French veterinary service (#E67-482-2). </plain></SENT>
<SENT sid="52" pm="."><plain>No surgery has been done on animals. </plain></SENT>
<SENT sid="53" pm="."><plain>Mice were euthanized according the European Community guidelines. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="54" pm="."><plain>2. </plain></SENT>
<SENT sid="55" pm="."><plain>Preparation and purification of mAb 17.2 </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>The mAb 17.2 (isotype IgG1, κ) was obtained by immunizing BALB/c mice with recombinant TcP2β [22]. </plain></SENT>
<SENT sid="57" pm="."><plain>The mAb was purified from ascitic fluid by precipitation with 40% ammonium sulphate at pH 7.4, followed by ion-exchange chromatography on a DEAE-Sephacel (Pharmacia, Sweden) column equilibrated in 17.5 mM NaCl at pH 8.0. </plain></SENT>
<SENT sid="58" pm="."><plain>The elution was done with 40 mM NaCl at pH 8.0. </plain></SENT>
<SENT sid="59" pm="."><plain>The sample was then dialyzed against 0.1 M potassium phosphate at pH 7.2. </plain></SENT>
</text></p><p><text><SENT sid="60" pm="."><plain>After addition of 5 mM β-mercaptoethanol and 2.5 mM EDTA, the IgG was treated with papain at an enzyme∶substrate ratio of 1∶100 at 37°C for 2 h. </plain></SENT>
<SENT sid="61" pm="."><plain>The reaction was stopped by addition of iodacetamide (1 mg/ml) before dialysis against 10 mM sodium phosphate at pH 8.0. </plain></SENT>
<SENT sid="62" pm="."><plain>The Fab was then added to a DEAE-Sephacel (Pharmacia, Sweden) column equilibrated with the same buffer. </plain></SENT>
<SENT sid="63" pm="."><plain>Fab 17.2 was eluted with phosphate buffer and then concentrated on a Centricon 10. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="64" pm="."><plain>3. </plain></SENT>
<SENT sid="65" pm="."><plain>Synthetic peptide </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>R13 peptide (EEEDDDMGFGLFD, representing the C-terminal region of TcP2β) was synthesized by the solid-phase method of Merrifield [28], with a semi-automatic multi-synthesizer NPS 4000 (Neosystem, France). </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="67" pm="."><plain>4. </plain></SENT>
<SENT sid="68" pm="."><plain>Crystallization of the complex Fab 17.2 </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>Crystals of apo Fab 17.2 and its complex with R13 were grown by vapour diffusion using the hanging drop technique. </plain></SENT>
<SENT sid="70" pm="."><plain>One volume of Fab 17.2 at 10 mg/ml was mixed with one volume of a solution consisting of 18% (w/v) PEG 8000, 0.1 M sodium cacodylate at pH 6.7, 0.2 M calcium acetate, 12.5 mM Tris-HCl pH 7.5 and 25 mM NaCl. </plain></SENT>
<SENT sid="71" pm="."><plain>The drop, with a final protein concentration of 4.2 mg/ml, was sealed over a reservoir containing 1 ml of mother liquor. </plain></SENT>
<SENT sid="72" pm="."><plain>Crystallization of the Fab 17.2/R13 peptide was performed under the same conditions as above with Fab and peptide concentrations of 15 mg/ml and 10 mg/ml, respectively, giving an Ab/antigen molar ratio ∼1/20. </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="73" pm="."><plain>5. </plain></SENT>
<SENT sid="74" pm="."><plain>Crystallographic data and structure solution </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>Diffraction data were collected on the beam lines ID14-1 (Fab 17.2/R13 complex) and BM30A (apo Fab 17.2) at the European Synchrotron Radiation Facility, Grenoble, France. </plain></SENT>
<SENT sid="76" pm="."><plain>The two crystal forms belong to space group P21 with very similar unit cell parameters. </plain></SENT>
<SENT sid="77" pm="."><plain>Diffraction data were integrated and scaled using the programs HKL and SCALEPACK [29]. </plain></SENT>
<SENT sid="78" pm="."><plain>The structure was solved by molecular replacement with the program AMoRe [30], using antibody variable and constant dimers derived from PDB entry 2igf as search models. </plain></SENT>
<SENT sid="79" pm="."><plain>Two independent Fab molecules, expected from the unit cell volume, were readily located and the structure was refined using the program autoBUSTER (Global Phasing Ltd.). </plain></SENT>
<SENT sid="80" pm="."><plain>Manual adjustments between refinement runs and building of the R13 peptide in the complex were performed with the program COOT [31]. </plain></SENT>
<SENT sid="81" pm="."><plain>Crystallographic parameters, diffraction data statistics and structure refinement results are summarized in Table 1. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pntd-0001375-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="82" pm="."><plain>Crystallographic data and refinement statistics. </plain></SENT>
</text></title></caption><alternatives><graphic id="pntd-0001375-t001-1" xlink:href="pntd.0001375.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1"/><td colspan="2" align="left" rowspan="1"><text><SENT sid="83" pm="."><plain>Fab 17.2 - R13(EEEDDDMGFGLFD) </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="84" pm="."><plain>Fab 17.2 apo </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="85" pm="."><plain>Space group </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="86" pm="."><plain>P21 </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="87" pm="."><plain>P21 </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Cell parameters </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>abc(Å) </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="90" pm="."><plain>83.0068.2192.11 </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="91" pm="."><plain>82.0765.6891.37 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>β (°) </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="93" pm="."><plain>98.4 </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="94" pm="."><plain>98.2 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="95" pm="."><plain>Resolution (Å) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>30.0–1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>1.94–1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>30.0–2.29 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>2.34–2.29 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="100" pm="."><plain>Total reflections </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>282283 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>144,460 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>2210 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="104" pm="."><plain>Unique reflections </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>73,918 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>3090 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>41,572 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>1458 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="109" pm="."><plain>Rmerge </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>0.077 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>0.405 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>0.049 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>0.170 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="114" pm="."><plain>Completeness (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>92.0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>57.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>94.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>50.7 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="119" pm="."><plain>δ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>14.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>2.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>22.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>4.2 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="124" pm="."><plain>Redundancy </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>3.82 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>3.82 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>3.47 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>3.47 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="129" pm="."><plain>B Wilson (Å2) </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="130" pm="."><plain>28.8 </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="131" pm="."><plain>28.8 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="132" pm="."><plain>Refinement </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="133" pm="."><plain>Resolution (Å) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>20.0–1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>1.94–1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>20.0–2.31 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>2.37–2.31 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="138" pm="."><plain>Rfactor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>0.1795 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>0.2107 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>0.1724 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>0.2013 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="143" pm="."><plain>Rfree </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>0.2178 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>0.2459 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>0.2355 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>0.3122 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="148" pm="."><plain>rms bonds (Å) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>0.010 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>0.010 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="151" pm="."><plain>rms angle (°) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>1.15 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>1.25 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="s2f"><title><text><SENT sid="154" pm="."><plain>6. β1-AR competition binding experiments </plain></SENT>
</text></title><p><text><SENT sid="155" pm="."><plain>HEK cells and HEK cells transfected with β1-AR (HEK-β1) were cultured in DMEM (GIBCO, Invitrogen, USA) with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine, using 200 µg/ml hygromycin B (Sigma, USA) for transfected cell maintenance [25]. </plain></SENT>
</text></p><p><text><SENT sid="156" pm="."><plain>HEK and HEK-β1 cells were seeded in FACS tubes at 8×105 cell/ml and incubated with mAb 40.14 or 17.2 (500 nM) or with mAb 17.2 (500 nM) pre-incubated for 2 h at 37°C with 10 µM R13 peptide in supplemented DMEM. </plain></SENT>
<SENT sid="157" pm="."><plain>After 1 h at room temperature, cells were stained with Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, USA) and propidium iodide (PI) to exclude the dead cell population. </plain></SENT>
<SENT sid="158" pm="."><plain>Cells were detected using a BD FACSARIA flow cytometer (BD Biosciences) and results were analysed with WinMdi 2.9 software (Copyright 1993–2000 Joseph Trotter). </plain></SENT>
<SENT sid="159" pm="."><plain>Values are expressed as means ± S.D. </plain></SENT>
<SENT sid="160" pm="."><plain>(n = 3) and statistical comparisons were performed using One-way and Two-way ANOVA with Bonferroni's Multiple Comparison post test using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">www.graphpad.com</ext-link>. P&lt;0.05 was considered statistically significant. </plain></SENT>
</text></p></sec><sec id="s2g"><title><text><SENT sid="161" pm="."><plain>7. </plain></SENT>
<SENT sid="162" pm="."><plain>Electrocardiogram recordings </plain></SENT>
</text></title><p><text><SENT sid="163" pm="."><plain>Three female BALB/c mice, 20 g each, were anesthetized using intraperitoneal Tribromoethanol 150 mg/Kg. </plain></SENT>
<SENT sid="164" pm="."><plain>The mAb 17.2 was injected intravenously at 200 nM in 200 µl of saline solution (0.9% NaCl). </plain></SENT>
<SENT sid="165" pm="."><plain>Electrocardiogram (ECG) recordings were performed during 30 min after injection. </plain></SENT>
<SENT sid="166" pm="."><plain>ECGs were obtained with the six standard leads (I, II, III, AVR, AVL, AVF) at 50 mm/s of paper speed and at 20 mm/mV amplitude using a Fukuda-Denshi Fx-2111 electrocardiograph (Tokyo, Japan) [32]. </plain></SENT>
<SENT sid="167" pm="."><plain>Electrocardiographic analysis included measurements of heart rate, P wave duration and amplitude, QRS complex duration and amplitude, P-R interval duration and a search for disturbances of rhythm, conduction, and repolarisation. </plain></SENT>
</text></p></sec><sec id="s2h"><title><text><SENT sid="168" pm="."><plain>8. </plain></SENT>
<SENT sid="169" pm="."><plain>Molecular modelling </plain></SENT>
</text></title><p><text><SENT sid="170" pm="."><plain>All procedures were performed with Discovery Studio 2.5 software from Accelrys (San Diego, CA, USA). </plain></SENT>
<SENT sid="171" pm="."><plain>The crystal structure of the turkey β1-AR (PDB 2VT4) was used as template to build a model of the human β1-AR. </plain></SENT>
<SENT sid="172" pm="."><plain>We mutated all residues to the human sequence and optimized the conformation of both the mutated residues and any surrounding residues that lay within a cut-off radius of 2 Å. </plain></SENT>
<SENT sid="173" pm="."><plain>Five models thus obtained were scored by the Discrete Optimized Protein Energy (DOPE). </plain></SENT>
<SENT sid="174" pm="."><plain>We continued analysis using the lowest energy model (DOPE = −39358.55 kcal/mol), which was superimposed onto a membrane model. </plain></SENT>
<SENT sid="175" pm="."><plain>The R13 epitope structure was aligned with the second extracellular loop of the humanized β1-AR model to allow positioning of the Ab on the putative cross-reactive epitope. </plain></SENT>
<SENT sid="176" pm="."><plain>Once the Ab was positioned, a fixed atom constraint was applied to the whole β1-AR with the exception of the extracellular regions and a harmonic restraint was applied to the frame work regions of the Ab. </plain></SENT>
<SENT sid="177" pm="."><plain>Finally, the complex was subjected to an initial minimization step (max 500), RMS gradient 0.1 Kcal/mol by conjugated gradient; followed by a second minimization step (max 500), RMS gradient 0.0001 Kcal/mol by conjugated gradient. </plain></SENT>
<SENT sid="178" pm="."><plain>The structure was then submitted to a dynamic simulation including heating (2000 steps), equilibration (1000 steps) and production (1000 steps) at 300 °K with a time step of 0.001 ps under a distance-dependent, dielectric constant, implicit solvent model. </plain></SENT>
<SENT sid="179" pm="."><plain>A negative intermolecular energy of −430 kcal/mol was obtained for the complex under these conditions. </plain></SENT>
<SENT sid="180" pm="."><plain>All images were generated using PyMOL Molecular Graphics System, Version 1.0, Schrödinger, LLC. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="181" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3a"><title><text><SENT sid="182" pm="."><plain>Structure of apo Fab 17.2 and its complex with R13 </plain></SENT>
</text></title><p><text><SENT sid="183" pm="."><plain>We determined the crystal structure of the Fab region of the mouse monoclonal antibody 17.2, in the apo form and in complex with the peptide R13 (EEEDDDMGFGLFD), corresponding to the C-terminal epitope of TcP2β. </plain></SENT>
<SENT sid="184" pm="."><plain>The asymmetric unit of both crystal structures contains two independent apo Fab molecules or Fab-R13 complexes (referred as molecule 1 and 2). </plain></SENT>
<SENT sid="185" pm="."><plain>The N- and C-termini of R13 show considerable mobility and only the first eleven amino acid residues (EEEDDDMGFGL) in both complexes could be traced in the electron density maps. </plain></SENT>
<SENT sid="186" pm="."><plain>The two independent Fab molecules of each crystal form show small differences in quaternary structure, as revealed by the difference in elbow angle (angle subtended by the pseudo two-fold axes of the variable and constant dimers). </plain></SENT>
<SENT sid="187" pm="."><plain>The Fab 17.2 elbow angles are 152/144° and 150/146° for the apo and R13 complex, respectively (molecule1/molecule2), and lie within the range of previously reported values [33]. </plain></SENT>
<SENT sid="188" pm="."><plain>These reflect the different lattice environments of the two independent molecules in the asymmetric unit since the respective elbow angles for molecules 1 and 2 are common to both crystal forms, which are closely isomorphous. </plain></SENT>
</text></p><p><text><SENT sid="189" pm="."><plain>No significant structural differences were observed between individual variable domains. </plain></SENT>
<SENT sid="190" pm="."><plain>A pair-wise superposition of all VL domains from the apo and R13 complex Fab molecules gives a mean r.m.s. difference in Cα position of 0.28 Å (range 0.23–0.34 Å). </plain></SENT>
<SENT sid="191" pm="."><plain>Similarly, the superimposed VH domains give a mean r.m.s. difference in Cα positions of 0.28 Å (range 0.23–0.33 Å). </plain></SENT>
<SENT sid="192" pm="."><plain>For both VH and VL, the largest differences occur between the R13 complex and apo forms, but these are small, showing that the polypeptide conformation was largely conserved upon binding the antigen. </plain></SENT>
<SENT sid="193" pm="."><plain>The most notable structural change to occur upon binding R13 is a small relative rotation between the VL and VH domains, leading to an opening out at the antigen-binding site when the antigen is bound, with a 4.2° rotation from the apo to R13 complex state for molecule 1 and 4.6° for molecule 2. </plain></SENT>
<SENT sid="194" pm="."><plain>The distance between the tips of CDR-L1 and CDR-H2 is correspondingly shifted from 15.7 Å and 16.8 Å in the apo structure to 18.9 Å and 18.2 Å in the R13 complex in molecules 1 and 2, respectively ( Figure 1 ). </plain></SENT>
<SENT sid="195" pm="."><plain>Interestingly, side chain conformations at the antigen binding site are entirely conserved upon binding the antigen ( Figure 2A ). </plain></SENT>
<SENT sid="196" pm="."><plain>In addition, there are six water molecules within the Fab 17.2 antigen combining site in the apo structure that are displaced by the peptide in the Fab 17.2 R13 complex ( Figure 2B ). </plain></SENT>
<SENT sid="197" pm="."><plain>Two of the water molecules in the apo structure are replaced by the side chains of Glu3 and Asp6, supporting the pivotal role of these residues in the antibody-antigen interaction. </plain></SENT>
<SENT sid="198" pm="."><plain>The remaining four waters are displaced by the main chain of the peptide, residues Met7 to Gly10 ( Figure 2C ). </plain></SENT>
<SENT sid="199" pm="."><plain>The complex structure also reveals two water-mediated interactions between the peptide and the CDR-H1 (Thr31 and Asn32) engaging both side and main chain atoms of a single epitope residue, Asp4. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pntd-0001375-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="200" pm="."><plain>Structure of the Fab 17.2. </plain></SENT>
</text></title><p><text><SENT sid="201" pm="."><plain>A. </plain></SENT>
<SENT sid="202" pm="."><plain>Apo Fab 17.2 structure (molecule 1). </plain></SENT>
<SENT sid="203" pm="."><plain>Heavy chain CDRs are coloured in red and light chain CDRs in blue. </plain></SENT>
<SENT sid="204" pm="."><plain>B. </plain></SENT>
<SENT sid="205" pm="."><plain>Superposition of molecules 1, VH-VL region of the two crystals asymmetric units. </plain></SENT>
<SENT sid="206" pm="."><plain>C. </plain></SENT>
<SENT sid="207" pm="."><plain>Superposition of molecules 2, VH-VL region of the two crystals asymmetric units. </plain></SENT>
<SENT sid="208" pm="."><plain>Apo Fab 17.2 (grey), Fab 17.2-R13 molecule 1 (green) and molecule 2 (magenta). </plain></SENT>
</text></p></caption><graphic xlink:href="pntd.0001375.g001"/></fig></SecTag><SecTag type="FIG"><fig id="pntd-0001375-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="209" pm="."><plain>Structure of the Fab17.2 – R13 complex. </plain></SENT>
</text></title><p><text><SENT sid="210" pm="."><plain>A. </plain></SENT>
<SENT sid="211" pm="."><plain>Superposition of the apo Fab 17.2 and R13 complex structures (grey and green respectively). </plain></SENT>
<SENT sid="212" pm="."><plain>VH and VL contact residues are indicated. </plain></SENT>
<SENT sid="213" pm="."><plain>B. </plain></SENT>
<SENT sid="214" pm="."><plain>Main water molecules present on the antigen binding site of Fab 17.2 apo. </plain></SENT>
<SENT sid="215" pm="."><plain>C. </plain></SENT>
<SENT sid="216" pm="."><plain>Superposition of water molecules present in the apo Fab 17.2 that are replaced by the peptide in the Fab 17.2 R13 complex. </plain></SENT>
<SENT sid="217" pm="."><plain>D. </plain></SENT>
<SENT sid="218" pm="."><plain>Superposition of R13 peptides from molecules 1 (green) and 2 (magenta). </plain></SENT>
<SENT sid="219" pm="."><plain>E. </plain></SENT>
<SENT sid="220" pm="."><plain>Structure of the Fab 17.2-R13 complex (molecule 1). </plain></SENT>
<SENT sid="221" pm="."><plain>All hydrogen bonds between mAb 17.2 and peptide R13 are illustrated as dotted yellow lines. </plain></SENT>
<SENT sid="222" pm="."><plain>The π-stacking interaction between VL Tyr101 and the epitope Phe9 is also indicated. </plain></SENT>
<SENT sid="223" pm="."><plain>Heavy chain CDRs are coloured in red and light chain CDRs in blue the peptide is coloured in light green. </plain></SENT>
</text></p></caption><graphic xlink:href="pntd.0001375.g002"/></fig></SecTag><p><text><SENT sid="224" pm="."><plain>The two bound R13 peptides from the complexes in the asymmetric unit are similar in structure, superimposing with an r.m.s. difference in Cα positions of 0.78 Å (1.06 Å for all main chain atoms). </plain></SENT>
<SENT sid="225" pm="."><plain>The peptide structures diverge most at the N- and C-termini, where contacts with the antibody are sparse, but are very similar in the central region of the peptide between residues Asp3 and Gly10 ( Figure 2D ). </plain></SENT>
<SENT sid="226" pm="."><plain>Antibody-peptide interactions are similar in the two independent Fab 17.2-R13 complexes and include 13 hydrogen bonds, four with VL and nine with VH, as well as a salt bridge between VH Arg52 and R13 Glu3 ( Table 2 ). </plain></SENT>
<SENT sid="227" pm="."><plain>In addition, an aromatic stacking interaction occurs between VL Tyr101 and R13 Phe9. </plain></SENT>
<SENT sid="228" pm="."><plain>These results highlight the importance of some key contact residues on the epitope, such as Glu3, Asp6 and Phe9 ( Figure 2E ). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pntd-0001375-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="229" pm="."><plain>Polar contacts between Fab 17.2 and R13 peptide. </plain></SENT>
</text></title></caption><alternatives><graphic id="pntd-0001375-t002-2" xlink:href="pntd.0001375.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>Fab </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>CHAIN </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>CDR </plain></SENT>
</text></td><td colspan="3" align="left" rowspan="1"><text><SENT sid="233" pm="."><plain>Atom [MC/SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>Ag </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Asn39 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>Nδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>Gly8 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>Arg51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>Nη2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>Asp6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Arg51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>Nη1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Asp6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>Gly96 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>N [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>Gly10 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>Thr31 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>N [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>Asp4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>Asn32 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>Nδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>Asp4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>Arg52 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>Nη1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>Oε2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>Glu3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>Ser53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>N [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>Oε1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>Glu3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>Ser53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Oγ [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>Oε1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>Glu3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>Asn56 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>Nδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>Oε1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>Glu3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>Thr102 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>N [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>Asp6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>Thr102 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>Oγ1 [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>Asp6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>Thr103 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>N [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>Asp6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>Thr103 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>Oγ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>Asp6 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p><text><SENT sid="333" pm="."><plain>MC: Main Chain; SC: Side Chain. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3b"><title><text><SENT sid="334" pm="."><plain>Functional activity of the mAb 17.2 </plain></SENT>
</text></title><p><text><SENT sid="335" pm="."><plain>The cross-reaction of anti-R13 Abs with β1-AR has been extensively reported [22], [23], [24], [34]. </plain></SENT>
<SENT sid="336" pm="."><plain>Indeed, the mAb 17.2, first described by Mahler et al (2001) [22], induced a dose-dependent increase on the beating frequency on neonatal rat cardiomyocytes culture that was abolished by bisoprolol, a specific β1-AR antagonist. </plain></SENT>
<SENT sid="337" pm="."><plain>Here, we show by flow cytometry that mAb 17.2 specifically recognized human β1-AR presented in a stable HEK-β1 cell line ( Figure 3A and B ). </plain></SENT>
<SENT sid="338" pm="."><plain>This cell line possesses a high receptor expression (800–1300 fmol/mg of total protein), as has been previously reported [35]. </plain></SENT>
<SENT sid="339" pm="."><plain>The mAb 40.14, which recognizes an internal epitope on TcP2β, gave no signal, indicating the specificity of mAb 17.2-β1-AR interaction ( Figure 3B ). </plain></SENT>
<SENT sid="340" pm="."><plain>In addition, this interaction was inhibited by pre-incubation of the mAb 17.2 with R13 peptide ( Figure 3B   inset). </plain></SENT>
<SENT sid="341" pm="."><plain>Furthermore, passive transfer of mAb 17.2 to naïve mice induced an increase in the beating rate from 240 bpm to 300 bpm after 30 minutes ( Figure 3C ). </plain></SENT>
<SENT sid="342" pm="."><plain>Repolarisation abnormalities (a) and first degree AV conduction block (b) were recorded at 15 and 30 minutes post-injection. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pntd-0001375-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="343" pm="."><plain>Functional activity of the mAb 17.2. </plain></SENT>
</text></title><p><text><SENT sid="344" pm="."><plain>A. </plain></SENT>
<SENT sid="345" pm="."><plain>Representative histogram showing the HEK and HEK-β1 cells labelled with mAb 17.2 followed by a Cy3-conjugated goat anti-mouse IgG. </plain></SENT>
<SENT sid="346" pm="."><plain>B. </plain></SENT>
<SENT sid="347" pm="."><plain>Results are expressed as means ± SD (n = 3). </plain></SENT>
<SENT sid="348" pm="."><plain>Inset: Binding of mAb 17.2 to HEK-β1 cells in the presence of R13 peptide. ** p&lt;0.01; *** p&lt;0.001. </plain></SENT>
<SENT sid="349" pm="."><plain>C. </plain></SENT>
<SENT sid="350" pm="."><plain>Passive transfer of mAb 17.2 to naïve mice. </plain></SENT>
<SENT sid="351" pm="."><plain>Repolarisation abnormalities (a) and first degree AV conduction block (b) are indicated by arrows. bpm: beats per minute. </plain></SENT>
</text></p></caption><graphic xlink:href="pntd.0001375.g003"/></fig></SecTag></sec><sec id="s3c"><title><text><SENT sid="352" pm="."><plain>Modelling the interaction with the human β1-AR </plain></SENT>
</text></title><p><text><SENT sid="353" pm="."><plain>In view of the functional activity of the Ab on β1-AR, we generated a model of the interaction of the Fab 17.2 with the human receptor from the crystal structure of the turkey homologue. </plain></SENT>
<SENT sid="354" pm="."><plain>Briefly, we generated a model of the human β1-AR as described under material and methods. </plain></SENT>
<SENT sid="355" pm="."><plain>The structure of TcP2β epitope, R13, was aligned to the humanized second extracellular loop (2ECL) of the model to allow positioning the Ab on the putative binding site ( Figure 4A ) and the complex was subjected to a two minimization steps followed by heating, equilibration and production protocols under a distance-dependent, dielectric-implicit solvent model ( Figure 4B ). </plain></SENT>
<SENT sid="356" pm="."><plain>The interaction energy of the complex Ab-β1-AR was estimated at −430 kcal/mol. </plain></SENT>
<SENT sid="357" pm="."><plain>Polar contacts found in the model are summarized in  Table 3 . </plain></SENT>
<SENT sid="358" pm="."><plain>Some of Ab residues identified in the interaction with the humanized 2ECL peptide were key residues in the interaction with the T. cruzi epitope, such as Thr31, Arg52 and Asn56 of the heavy chain. </plain></SENT>
<SENT sid="359" pm="."><plain>In addition, the acidic residues present on the humanized β1-AR model (Asp187, Glu188, Asp195 and Asp200) established many hydrogen bonds with different residues of the Fab ( Figure 4C ). </plain></SENT>
<SENT sid="360" pm="."><plain>Remarkably, while the light chain established just a few contact points with the T. cruzi epitope, it established many hydrogen bonds with β1-AR, as can be seen in  Figure 4   and   Table 3 , suggesting an important role in stabilizing the interaction with the receptor. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pntd-0001375-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.g004</object-id><label>Figure 4</label><caption><title><text><SENT sid="361" pm="."><plain>Model of the interaction of Fab 17.2 with the human β1-AR. </plain></SENT>
</text></title><p><text><SENT sid="362" pm="."><plain>A. </plain></SENT>
<SENT sid="363" pm="."><plain>Superposition of the second extracellular loop (2ECL) of the human β1-AR model (violet) and the region 2–5 of the epitope (light green). </plain></SENT>
<SENT sid="364" pm="."><plain>B. </plain></SENT>
<SENT sid="365" pm="."><plain>Complex of the Fab 17.2 (light green) with the human β1-AR (violet) inserted in a membrane model (grey). </plain></SENT>
<SENT sid="366" pm="."><plain>C. </plain></SENT>
<SENT sid="367" pm="."><plain>Zoom of the paratope region of 17.2 interacting with the second extracellular loop. </plain></SENT>
<SENT sid="368" pm="."><plain>The main contact points are illustrated as dotted yellow lines. </plain></SENT>
<SENT sid="369" pm="."><plain>Heavy chain CDRs are coloured in red and light chain CDRs in blue. </plain></SENT>
</text></p></caption><graphic xlink:href="pntd.0001375.g004"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pntd-0001375-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="370" pm="."><plain>Polar contacts in the model between 17.2 and β1-AR. </plain></SENT>
</text></title></caption><alternatives><graphic id="pntd-0001375-t003-3" xlink:href="pntd.0001375.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>mAb </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>CHAIN </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>CDR </plain></SENT>
</text></td><td colspan="3" align="left" rowspan="1"><text><SENT sid="374" pm="."><plain>Atom [MC/SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>β-1AR </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>Gln27 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>Oε1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>Hη22[SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>Arg323 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>Ser28 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>Oγ[SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>Hη11[SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>Arg323 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>Asp31 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>Hω[MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>Arg323 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>Ser32 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>Oγ[SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>Hω[MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>Val326 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>Lys35 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>Hζ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>Asp200 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>Lys35 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>Hζ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>Asp200 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>Lys35 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>Hζ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>Asp200 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>Lys58 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>Hζ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>Lys197 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>Lys58 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>Hζ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>Asp195 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>Lys58 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>Hζ3 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>Asp195 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>Lys58 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>Hζ3 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>Asp195 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>His98 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>Hδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>Asp322 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>Thr31 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>Hγ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>Oδ2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>Asp187 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>Asn32 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>Hδ22[SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>Asp187 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>Arg50 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>Hη22 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>Oε1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>Glu188 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>Arg52 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>Hη12 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>Oε2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>Glu188 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>Arg52 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>Hη22 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>Oε2 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>Glu188 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>Asn56 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>Hη11 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>Arg317 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>Asn57 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>Hη11 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>Arg205 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>Asn57 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="513" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>Hη12 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain>Arg205 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>Ser59 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>Oγ[SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>Hη12 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>Arg205 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>Ser59 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="526" pm="."><plain>Oγ[SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="527" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain>Hη22 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>Arg205 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>Tyr61 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="532" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="533" pm="."><plain>Hη [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="534" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="535" pm="."><plain>O [MC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="536" pm="."><plain>Phe315 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="537" pm="."><plain>Arg100 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="538" pm="."><plain>H </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="539" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="540" pm="."><plain>Hη21 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="541" pm="."><plain>… </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>Oδ1 [SC] </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="543" pm="."><plain>Asp187 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p><text><SENT sid="544" pm="."><plain>MC: Main Chain; SC: Side Chain. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="545" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="546" pm="."><plain>Alanine-mutation scanning analysis on the R13 epitope showed the importance of Glu3, Asp5, Asp6, Gly8 and Phe9 for mAb 17.2 recognition [22]. </plain></SENT>
<SENT sid="547" pm="."><plain>Crystal structure confirmed the interaction of Glu3, Asp6, Gly8 and Phe9 with the antibody and exposed a polar contact between Asp5 and Met7. </plain></SENT>
<SENT sid="548" pm="."><plain>This interaction may contribute to stabilize the conformation of the peptide that was shown to behave as random coil in solution [36]. </plain></SENT>
</text></p><p><text><SENT sid="549" pm="."><plain>Despite the sequence similarity between the epitope sequence (EEEDDDMGFGL) of TcP2β and the acidic region on the human second extracellular loop (AESDEA) of β1-AR, crystallographic data and modelling showed that this minimal region is involved but not sufficient for an effective interaction. </plain></SENT>
<SENT sid="550" pm="."><plain>The interaction energy between the Fab and the whole receptor was estimated at −430 kcal/mol. </plain></SENT>
<SENT sid="551" pm="."><plain>However, the interaction energy of the Ab with only the 2ECL was −283 kcal/mol, suggesting that other regions on the receptor contribute to stabilize the interaction within the complex. </plain></SENT>
<SENT sid="552" pm="."><plain>These data could also explain the low affinity of mAb 17.2, or single chain derived recombinant antibodies, with the β1-AR 2ECL peptide H26R measured by surface plasmon resonance [22], [25]. </plain></SENT>
<SENT sid="553" pm="."><plain>It is possible that electrostatic forces guide the first contacts between an electropositive antigen-binding pocket and the electronegative region of the 2ECL, with the heavy and light chains establishing additional contacts with the receptor. </plain></SENT>
<SENT sid="554" pm="."><plain>Comparison of the buried surfaces in both crystallized complex and the model ( Table 4 ) shows a larger surface for the complex with the β1-AR, supporting this hypothesis. </plain></SENT>
<SENT sid="555" pm="."><plain>However, the shape complementarities for the model-Fab complex were smaller in comparison to R13 complex ( Table 4 ), suggesting a reduced affinity for the β1-AR. </plain></SENT>
<SENT sid="556" pm="."><plain>Together, these data support the idea of a bystander activity of mAb 17.2 on the cardiac receptor rather than classical epitope mimicry of acidic residues. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pntd-0001375-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001375.t004</object-id><label>Table 4</label><caption><title><text><SENT sid="557" pm="."><plain>Buried surface upon complex formation, with shape complementarities (Sc) [50] and number of contacts observed between the mAb 17.2 and the R13 peptide in the crystal structure1 and the model2. </plain></SENT>
</text></title></caption><alternatives><graphic id="pntd-0001375-t004-4" xlink:href="pntd.0001375.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="558" pm="."><plain>Fab17.2 – R131 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="559" pm="."><plain>Fab17.2 - β1AR2 </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="560" pm="."><plain>Surface (Å2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="561" pm="."><plain>Ab (VL/VH) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="562" pm="."><plain>648 (252.7/395.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="563" pm="."><plain>1414.9 (868.3/546.6) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="564" pm="."><plain>Ag </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="565" pm="."><plain>845 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="566" pm="."><plain>2972.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="567" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="568" pm="."><plain>1493 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="569" pm="."><plain>4387 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="570" pm="."><plain>Sc </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="571" pm="."><plain>0.77 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="572" pm="."><plain>0.614 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="573" pm="."><plain>N° contacts </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="574" pm="."><plain>Polar </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="575" pm="."><plain>14 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="576" pm="."><plain>46 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="577" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="578" pm="."><plain>32 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="579" pm="."><plain>96 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="580" pm="."><plain>Recently, the crystal structure of turkey β1-AR in complex with different agonists and antagonists was published [37]. </plain></SENT>
<SENT sid="581" pm="."><plain>In this work, the authors showed the presence of structural differences between the 2ECL of the β1-AR bound to the agonist dobutamine (PDB 2Y01) and to the antagonist cyanopindolol (PDB2VT4). </plain></SENT>
<SENT sid="582" pm="."><plain>A 1 Å contraction of the ligand-binding pocket between helices H5 and H7 was observed in the agonist complex relative to the antagonist complex. </plain></SENT>
<SENT sid="583" pm="."><plain>The contraction of the catecholamine-binding pocket induced a conformational change in the 2ECL [37]. </plain></SENT>
<SENT sid="584" pm="."><plain>In addition, we previously reported the construction of two single chain recombinant antibodies (scFv) derived from the mAb 17.2, named scFv C5 and B7 [25]. </plain></SENT>
<SENT sid="585" pm="."><plain>Both scFv were able to recognize T. cruzi ribosomal P proteins and β1-AR in Western blot, ELISA, surface plasmon resonance and immunofluorescence. </plain></SENT>
<SENT sid="586" pm="."><plain>In functional assays, however, the monomeric scFv B7 behaved as a β1-AR antagonist, while the dimeric scFv C5 acted as a β1-AR agonist. </plain></SENT>
<SENT sid="587" pm="."><plain>The interaction of the Fab fragment with the β1-AR should thus correspond to an antagonist conformation. </plain></SENT>
<SENT sid="588" pm="."><plain>A dimeric interaction of the Ab with the receptor would, however, be constrained by the distance of the two antigen-binding sites on the dimeric Ab. </plain></SENT>
<SENT sid="589" pm="."><plain>Since β1-AR forms a family of dimeric membrane proteins, we suggested that the interaction constraints between the two dimers require a small rearrangement of the receptor dimer, decreasing the pharmacophore pocket, as has been described for partial agonists [37]. </plain></SENT>
<SENT sid="590" pm="."><plain>This could explain the experimental observation that monomeric fragments of Abs against the second extracellular loops of β1-AR act as inverse agonists while the bivalent fragments or dimeric antibodies behave as partial agonists [25], [38], [39], [40]. </plain></SENT>
</text></p><p><text><SENT sid="591" pm="."><plain>The clinical relevance of auto-reactive Abs in the context of the pathogenesis of cChHD is still controversial. </plain></SENT>
<SENT sid="592" pm="."><plain>Chronic Chagas' patients develop Abs against G protein-coupled receptors such as β1-AR, β2-AR and M2-AChR and there are different profiles of these Abs accordingly with the clinical outcome [23], [41], [42]. </plain></SENT>
<SENT sid="593" pm="."><plain>In the case of cChHD, there is a prevalence of β1-AR and M2-AChR Abs [43]. </plain></SENT>
<SENT sid="594" pm="."><plain>Interestingly these Abs can be detected before the clinical manifestations, supporting the hypothesis of Abs as pathogenic driver for clinical manifestations such as cardiomyopathy or megacolon [43]. </plain></SENT>
<SENT sid="595" pm="."><plain>It is well documented that chronic adrenergic stimulation mediated by antibodies may have a cardio-toxic effect resembling that caused by catecholamine, which induce cardiac changes similar to those observed in Chagas' disease; namely induction of micro focal lesions associated with a mononuclear cell infiltrate with increased involvement of the left ventricle, and particularly the left ventricular apex [44], [45], [46], [47], [48]. </plain></SENT>
<SENT sid="596" pm="."><plain>Moreover, IgGs from cChHD patients as well as the monoclonal antibody 17.2 were able to provoke apoptosis on HL-1 cardiac cell line, effect that was diminished by either R13 peptide or propranolol [26], reinforcing the pathogenic role of anti-R13 Abs acting on the β1-AR. </plain></SENT>
</text></p><p><text><SENT sid="597" pm="."><plain>Our data provide a molecular basis for the understanding of the ß1-AR bystander activation by anti-R13 Abs. </plain></SENT>
<SENT sid="598" pm="."><plain>Furthermore, as severe cases of chronic Chagas' Heart Disease are related to high levels of Abs directed against the R13 epitope [8], [17], [18], [19], [20], [23], [49], and immuno-purified anti-R13 Abs from some of these patients showed in common that R13 residues Glu3, Asp6 and Phe9 were essential for recognition [23] (as was shown for mAb 17.2), we suggest that high blood concentrations of these antibodies may exert a systemic effect by inducing functional changes in cell types and tissues expressing this receptor, thereby increasing liability to chronic pathology from T. cruzi infection. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="599" pm="."><plain>We thank Dr. Sylviane Muller and Prof. </plain></SENT>
<SENT sid="600" pm="."><plain>Sylvie Fournel (UPR 9021 Strasbourg, France) for helpful collaboration in the publication of this article; Maximiliano Juri-Ayub and Josiane Gregoire for production and purification of mAb 17.2 and A. </plain></SENT>
<SENT sid="601" pm="."><plain>Benatar for his collaboration with FACS experiments. </plain></SENT>
<SENT sid="602" pm="."><plain>HEK-β1 cells were kindly provided by Dr. Federico Mayor Jr. </plain></SENT>
<SENT sid="603" pm="."><plain>(Universidad Autónoma de Madrid, Spain). </plain></SENT>
<SENT sid="604" pm="."><plain>We thank the staff of the European Synchrotron Radiation Facility, Grenoble, France, for providing facilities for diffraction measurements and for assistance. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="605" pm="."><plain>In memory of Dr. Mariano J. </plain></SENT>
<SENT sid="606" pm="."><plain>Levin (1951–2010), Director of the Laboratory of Molecular Biology of Chagas' disease, INGEBI-CONICET, Buenos Aires, Argentina, from 1985 to 2010. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="607" pm="."><plain>Author Information </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="608" pm="."><plain>Coordinates have been submitted to the PDB database under accession codes 3SGD and 3SGE for Fab 17.2 apo and Fab 17.2-R13 complex respectively. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="609" pm="."><plain>The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn fn-type="financial-disclosure"><p><text4fund><text><SENT sid="610" pm="."><plain>This work was supported by the Pasteur Institute, Paris; Agencia Nacional de Promoción Científica y Tecnológica, Argentina (ANPCyT; BID 1728/OC-AR PICT N° 25845) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. </plain></SENT>
<SENT sid="611" pm="."><plain>Support of CNRS-CONICET and INSERM-CONICET collaborative French-Argentinean research grants, as well as the ECOS-Sud project “Anticorps Anti-Proteines Ribosomales P de T. cruzi comme Inhibiteur Specifique de la Traduction” (France-Argentine, 2005–2008) are acknowledged. </plain></SENT>
<SENT sid="612" pm="."><plain>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="pntd.0001375-Moncayo1"><text><SENT sid="613" pm="."><plain>1 MoncayoASilveiraAC 2009 Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 104 Suppl 1 17 30 19753454 </plain></SENT>
</text></ref><ref id="pntd.0001375-Schofield1"><text><SENT sid="614" pm="."><plain>2 SchofieldCJJanninJSalvatellaR 2006 The future of Chagas disease control. Trends Parasitol 22 583 588 17049308 </plain></SENT>
</text></ref><ref id="pntd.0001375-Control1"><text><SENT sid="615" pm="."><plain>3 2002 Control of Chagas disease. World Health Organ Tech Rep Ser 905 i vi, 1–109, back cover 12092045 </plain></SENT>
</text></ref><ref id="pntd.0001375-Hontebeyrie1"><text><SENT sid="616" pm="."><plain>4 HontebeyrieMBrenièreSFAznarC 2010 Others forms of transmission in American Trypanosomiasis Chagas disease, One hundred years of research. edited by J Telleria and M Tibayrenc, Elsevier 583 597  </plain></SENT>
</text></ref><ref id="pntd.0001375-Rassi1"><text><SENT sid="617" pm="."><plain>5 RassiAJrRassiAMarin-NetoJA Chagas disease. Lancet 375 1388 1402  </plain></SENT>
</text></ref><ref id="pntd.0001375-Rassi2"><text><SENT sid="618" pm="."><plain>6 RassiAJrRassiALittleWC 2000 Chagas' heart disease. Clin Cardiol 23 883 889 11129673 </plain></SENT>
</text></ref><ref id="pntd.0001375-Elizari1"><text><SENT sid="619" pm="."><plain>7 ElizariMVChialePA 1993 Cardiac arrhythmias in Chagas' heart disease. J Cardiovasc Electrophysiol 4 596 608 8269325 </plain></SENT>
</text></ref><ref id="pntd.0001375-Chiale1"><text><SENT sid="620" pm="."><plain>8 ChialePAFerrariI 2001 Autoantibodies in Chagas' cardiomyopathy and arrhythmias. Autoimmunity 34 205 210 11908779 </plain></SENT>
</text></ref><ref id="pntd.0001375-Koberle1"><text><SENT sid="621" pm="."><plain>9 KoberleF 1968 Chagas' disease and Chagas' syndromes: the pathology of American trypanosomiasis. Adv Parasitol 6 63 116 4239747 </plain></SENT>
</text></ref><ref id="pntd.0001375-Palmieri1"><text><SENT sid="622" pm="."><plain>10 PalmieriJRLaChanceMAConnerDH 1984 Parasitic infection of the peripheral nervous system. DyckPJThjomasPKLambertEHBungeR Peripheral Neuropathy 2 1988 2009  </plain></SENT>
</text></ref><ref id="pntd.0001375-Kierszenbaum1"><text><SENT sid="623" pm="."><plain>11 KierszenbaumF 1999 Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev 12 210 223 10194457 </plain></SENT>
</text></ref><ref id="pntd.0001375-MarinNeto1"><text><SENT sid="624" pm="."><plain>12 Marin-NetoJACunha-NetoEMacielBCSimoesMV 2007 Pathogenesis of chronic Chagas heart disease. Circulation 115 1109 1123 17339569 </plain></SENT>
</text></ref><ref id="pntd.0001375-Hontebeyrie2"><text><SENT sid="625" pm="."><plain>13 HontebeyrieMTruyensCBrenièreSF 2010 Pathological consequences of host response to parasite in American Trypanosomiasis Chagas disease, One hundred years of reresearch. edited by J Telleria and M Tibayrenc, Elsevier 669 690  </plain></SENT>
</text></ref><ref id="pntd.0001375-Brandariz1"><text><SENT sid="626" pm="."><plain>14 BrandarizSSchijmanAViglianoCArtemanPViottiR 1995 Detection of parasite DNA in Chagas' heart disease. Lancet 346 1370 1371  </plain></SENT>
</text></ref><ref id="pntd.0001375-Aznar1"><text><SENT sid="627" pm="."><plain>15 AznarCLopez-BergamiPBrandarizSMarietteCLiegeardP 1995 Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infection. FEMS Immunol Med Microbiol 12 231 238 8745008 </plain></SENT>
</text></ref><ref id="pntd.0001375-Levin1"><text><SENT sid="628" pm="."><plain>16 LevinMJMesriEBenarousRLevitusGSchijmanA 1989 Identification of major Trypanosoma cruzi antigenic determinants in chronic Chagas' heart disease. Am J Trop Med Hyg 41 530 538 2479275 </plain></SENT>
</text></ref><ref id="pntd.0001375-Mesri1"><text><SENT sid="629" pm="."><plain>17 MesriEALevitusGHontebeyrie-JoskowiczMDighieroGVan RegenmortelMH 1990 Major Trypanosoma cruzi antigenic determinant in Chagas' heart disease shares homology with the systemic lupus erythematosus ribosomal P protein epitope. J Clin Microbiol 28 1219 1224 1696282 </plain></SENT>
</text></ref><ref id="pntd.0001375-Levitus1"><text><SENT sid="630" pm="."><plain>18 LevitusGHontebeyrie-JoskowiczMVan RegenmortelMHLevinMJ 1991 Humoral autoimmune response to ribosomal P proteins in chronic Chagas heart disease. Clin Exp Immunol 85 413 417 1893622 </plain></SENT>
</text></ref><ref id="pntd.0001375-Elies1"><text><SENT sid="631" pm="."><plain>19 EliesRFerrariIWallukatGLebesgueDChialeP 1996 Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J Immunol 157 4203 4211 8892658 </plain></SENT>
</text></ref><ref id="pntd.0001375-Kaplan1"><text><SENT sid="632" pm="."><plain>20 KaplanDFerrariIBergamiPLMahlerELevitusG 1997 Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. Proc Natl Acad Sci U S A 94 10301 10306 9294205 </plain></SENT>
</text></ref><ref id="pntd.0001375-Ferrari1"><text><SENT sid="633" pm="."><plain>21 FerrariILevinMJWallukatGEliesRLebesgueD 1995 Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 182 59 65 7790824 </plain></SENT>
</text></ref><ref id="pntd.0001375-Mahler1"><text><SENT sid="634" pm="."><plain>22 MahlerESepulvedaPJeannequinOLiegeardPGounonP 2001 A monoclonal antibody against the immunodominant epitope of the ribosomal P2beta protein of Trypanosoma cruzi interacts with the human beta 1-adrenergic receptor. Eur J Immunol 31 2210 2216 11449375 </plain></SENT>
</text></ref><ref id="pntd.0001375-Mahler2"><text><SENT sid="635" pm="."><plain>23 MahlerEHoebekeJLevinMJ 2004 Structural and functional complexity of the humoral response against the Trypanosoma cruzi ribosomal P2 beta protein in patients with chronic Chagas' heart disease. Clin Exp Immunol 136 527 534 15147356 </plain></SENT>
</text></ref><ref id="pntd.0001375-Sepulveda1"><text><SENT sid="636" pm="."><plain>24 SepulvedaPLiegeardPWallukatGLevinMJHontebeyrieM 2000 Modulation of cardiocyte functional activity by antibodies against trypanosoma cruzi ribosomal P2 protein C terminus. Infect Immun 68 5114 5119 10948133 </plain></SENT>
</text></ref><ref id="pntd.0001375-Smulski1"><text><SENT sid="637" pm="."><plain>25 SmulskiCLabovskyVLevyGHontebeyrieMHoebekeJ 2006 Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2beta protein and the human beta1 adrenergic receptor. FASEB J 20 1396 1406 16816115 </plain></SENT>
</text></ref><ref id="pntd.0001375-Levy1"><text><SENT sid="638" pm="."><plain>26 LevyGVTassoLMLonghiSARivelloHGKytoV 2011 Antibodies against the Trypanosoma cruzi ribosomal P proteins induce apoptosis in HL-1 cardiac cells. Int J Parasitol 41 635 644 21255576 </plain></SENT>
</text></ref><ref id="pntd.0001375-Warne1"><text><SENT sid="639" pm="."><plain>27 WarneTSerrano-VegaMJBakerJGMoukhametzianovREdwardsPC 2008 Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454 486 491 18594507 </plain></SENT>
</text></ref><ref id="pntd.0001375-Muller1"><text><SENT sid="640" pm="."><plain>28 MullerSCouppezMBriandJPGordonJSautiereP 1985 Antigenic structure of histone H2B. Biochim Biophys Acta 827 235 246 2578822 </plain></SENT>
</text></ref><ref id="pntd.0001375-Otwinowski1"><text><SENT sid="641" pm="."><plain>29 OtwinowskiZMinorWCarterCharlesWJr 1997 [20] Processing of X-ray diffraction data collected in oscillation mode. 307 326 Methods in Enzymology: Academic Press  </plain></SENT>
</text></ref><ref id="pntd.0001375-Navaza1"><text><SENT sid="642" pm="."><plain>30 NavazaJ 1994 AMoRe: an automated package for molecular replacement. Acta Crystallographica Section A 50 157 163  </plain></SENT>
</text></ref><ref id="pntd.0001375-Emsley1"><text><SENT sid="643" pm="."><plain>31 EmsleyPCowtanK 2004 Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60 2126 2132 15572765 </plain></SENT>
</text></ref><ref id="pntd.0001375-LopezBergami1"><text><SENT sid="644" pm="."><plain>32 Lopez BergamiPScaglioneJLevinMJ 2001 Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic. FASEB J 15 2602 2612 11726536 </plain></SENT>
</text></ref><ref id="pntd.0001375-Stanfield1"><text><SENT sid="645" pm="."><plain>33 StanfieldRLZemlaAWilsonIARuppB 2006 Antibody elbow angles are influenced by their light chain class. J Mol Biol 357 1566 1574 16497332 </plain></SENT>
</text></ref><ref id="pntd.0001375-Mahler3"><text><SENT sid="646" pm="."><plain>34 MahlerMKessenbrockKRaatsJWilliamsRFritzlerMJ 2003 Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med 81 194 204 12682728 </plain></SENT>
</text></ref><ref id="pntd.0001375-Tutor1"><text><SENT sid="647" pm="."><plain>35 TutorASPenelaPMayorFJr 2007 Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Cardiovasc Res 76 51 60 17628514 </plain></SENT>
</text></ref><ref id="pntd.0001375-Soares1"><text><SENT sid="648" pm="."><plain>36 SoaresMRBischPMCampos de CarvalhoACValenteAPAlmeidaFC 2004 Correlation between conformation and antibody binding: NMR structure of cross-reactive peptides from T. cruzi, human and L. braziliensis. FEBS Lett 560 134 140 14988012 </plain></SENT>
</text></ref><ref id="pntd.0001375-Warne2"><text><SENT sid="649" pm="."><plain>37 WarneTMoukhametzianovRBakerJGNehmeREdwardsPC 2011 The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 469 241 244 21228877 </plain></SENT>
</text></ref><ref id="pntd.0001375-Peter1"><text><SENT sid="650" pm="."><plain>38 PeterJCWallukatGTuglerJMauriceDRoegelJC 2004 Modulation of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2 receptor antibody fragments. J Biol Chem 279 55697 55706 15485827 </plain></SENT>
</text></ref><ref id="pntd.0001375-Peter2"><text><SENT sid="651" pm="."><plain>39 PeterJCEftekhariPBillialdPWallukatGHoebekeJ 2003 scFv single chain antibody variable fragment as inverse agonist of the beta2-adrenergic receptor. J Biol Chem 278 36740 36747 12860977 </plain></SENT>
</text></ref><ref id="pntd.0001375-Mijares1"><text><SENT sid="652" pm="."><plain>40 MijaresALebesgueDWallukatGHoebekeJ 2000 From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-beta(2)-adrenoceptor antibody behave as antagonists. Mol Pharmacol 58 373 379 10908305 </plain></SENT>
</text></ref><ref id="pntd.0001375-SterinBorda1"><text><SENT sid="653" pm="."><plain>41 Sterin-BordaLBordaE 2000 Role of neurotransmitter autoantibodies in the pathogenesis of chagasic peripheral dysautonomia. Ann N Y Acad Sci 917 273 280 11270349 </plain></SENT>
</text></ref><ref id="pntd.0001375-Labovsky1"><text><SENT sid="654" pm="."><plain>42 LabovskyVSmulskiCRGomezKLevyGLevinMJ 2007 Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin Exp Immunol 148 440 449 17419712 </plain></SENT>
</text></ref><ref id="pntd.0001375-Wallukat1"><text><SENT sid="655" pm="."><plain>43 WallukatGMunoz SaraviaSGHaberlandABartelSAraujoR 2010 Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. </plain></SENT>
<SENT sid="656" pm="."><plain>Their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 55 463 468 20117461 </plain></SENT>
</text></ref><ref id="pntd.0001375-Mao1"><text><SENT sid="657" pm="."><plain>44 MaoWFukuokaSIwaiCLiuJSharmaVK 2007 Cardiomyocyte apoptosis in autoimmune cardiomyopathy: mediated via endoplasmic reticulum stress and exaggerated by norepinephrine. Am J Physiol Heart Circ Physiol 293 H1636 1645 17545481 </plain></SENT>
</text></ref><ref id="pntd.0001375-Jahns1"><text><SENT sid="658" pm="."><plain>45 JahnsRSchlippABoivinVLohseMJ 2010 Targeting receptor antibodies in immune cardiomyopathy. Semin Thromb Hemost 36 212 218 20414837 </plain></SENT>
</text></ref><ref id="pntd.0001375-Nussinovitch1"><text><SENT sid="659" pm="."><plain>46 NussinovitchUShoenfeldY 2010 The Clinical Significance of Anti-Beta-1 Adrenergic Receptor Autoantibodies in Cardiac Disease. Clin Rev Allergy Immunol  </plain></SENT>
</text></ref><ref id="pntd.0001375-Nussinovitch2"><text><SENT sid="660" pm="."><plain>47 NussinovitchUShoenfeldY 2011 The Diagnostic and Clinical Significance of Anti-Muscarinic Receptor Autoantibodies. Clin Rev Allergy Immunol  </plain></SENT>
</text></ref><ref id="pntd.0001375-Rosenbaum1"><text><SENT sid="661" pm="."><plain>48 RosenbaumMBChialePASchejtmanDLevinMElizariMV 1994 Antibodies to beta-adrenergic receptors disclosing agonist-like properties in idiopathic dilated cardiomyopathy and Chagas' heart disease. J Cardiovasc Electrophysiol 5 367 375 8019712 </plain></SENT>
</text></ref><ref id="pntd.0001375-Levin2"><text><SENT sid="662" pm="."><plain>49 LevinMJKaplanDFerrariIArtemanPVazquezM 1993 Humoral autoimmune response in Chagas' disease: Trypanosoma cruzi ribosomal antigens as immunizing agents. FEMS Immunol Med Microbiol 7 205 210 7506093 </plain></SENT>
</text></ref><ref id="pntd.0001375-Lawrence1"><text><SENT sid="663" pm="."><plain>50 LawrenceMCColmanPM 1993 Shape complementarity at protein/protein interfaces. J Mol Biol 234 946 950 8263940 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
